A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Crafton SM, Salani R. Beyond chemotherapy: an overview and review of targeted therapy in cervical cancer. Clin Ther. 2016;38(3):449–458. doi:10.1016/j.clinthera.2016.02.00726926322
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeong D, Han Y-S, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015;89(1):1–8. doi:10.4174/astr.2015.89.1.126131438
   PubMed Web of Science ®Google Scholar
• Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 1996;7(2):213–221.8822205
   PubMedGoogle Scholar
• Stafl A, Mattingly RF. Angiogenesis of cervical neoplasia. Am J Obstet Gynecol. 1975;121(6):845–852.1119492
   PubMed Web of Science ®Google Scholar
• Obermair A, Wanner C, Bilgi S, et al. Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. Am J Obstet Gynecol. 1998;178(2):314–319. doi:10.1016/s0002-9378(98)80018-59500492
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–743. doi:10.1056/NEJMoa130974824552320
   PubMed Web of Science ®Google Scholar
• Minion LE, Tewari KS. Cervical cancer – state of the science: from angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018;148(3):609–621. doi:10.1016/j.ygyno.2018.01.00929666026
   PubMed Web of Science ®Google Scholar
• Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137–4147. doi:10.2147/OTT.S17230530050305
   PubMed Web of Science ®Google Scholar
• Qiu H, Li J, Liu Q, Tang M, Wang Y. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle. 2018;17(10):1235–1244. doi:10.1080/15384101.2018.147131529886786
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097–1105. doi:10.1177/194760191142303122866201
   PubMedGoogle Scholar
• Jo JC, Hong YS, Kim KP, et al. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs. 2014;32(2):369–376. doi:10.1007/s10637-013-0059-024425345
   PubMed Web of Science ®Google Scholar
• Bender D, Sill MW, Lankes HA, et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;138(3):507–512.26186911
   PubMed Web of Science ®Google Scholar
• Chan JK, Deng W, Higgins RV, et al. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;146(3):554–559.28728751
   PubMed Web of Science ®Google Scholar
• Zhou JG, Zhou NJ, Zhang Q, Feng YY, Zhou H. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. Trials. 2018;19(1):500.30223869
   PubMedGoogle Scholar
• Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: what is the way forward. World J Gastroenterol. 2018;24(29):3222–3238.30090003
   PubMed Web of Science ®Google Scholar
• Hou XF, Xu LP, Song HY, et al. ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA. World J Gastroenterol. 2017;23(10):1796–1803.28348485
   PubMed Web of Science ®Google Scholar
• Liu ZL, Jin BJ, Cheng CG, et al. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(23):5370–5377.29243778
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014,370(8):734–743.
   Google Scholar
• Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–1663.28756902
   PubMed Web of Science ®Google Scholar
• Minion LE, Bai J, Monk BJ, et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol. 2015;137(3):490–496.25766118
   PubMed Web of Science ®Google Scholar
• William Carpenter J. Living in China on $1,000 a month. Avaialble from: https://www.investopedia.com/articles/personal-finance/011416/living-china-1000-month.asp. Accessed 1011, 2018.
   Google Scholar
• Alldredge JK, Tewari KS. Clinical trials of antiangiogenesis therapy in recurrent/persistent and metastatic cervical cancer. Oncologist. 2016;21(5):576–585.27026677
   PubMed Web of Science ®Google Scholar
• Rugo HS, Chien AJ, Franco SX, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012;134(1):13–20.22198412
   PubMed Web of Science ®Google Scholar